Risk of squamous cell carcinoma in patients with hidradenitis suppurativa treated with anti-TNF-alpha-Results from a 12-year multicentric observational prospective study
Language English Country England, Great Britain Media print-electronic
Document type Journal Article, Multicenter Study, Observational Study
PubMed
38407515
DOI
10.1111/jdv.19916
Knihovny.cz E-resources
- MeSH
- Adult MeSH
- Hidradenitis Suppurativa * drug therapy complications MeSH
- Infliximab therapeutic use MeSH
- Middle Aged MeSH
- Humans MeSH
- Skin Neoplasms drug therapy MeSH
- Prospective Studies MeSH
- Carcinoma, Squamous Cell * drug therapy MeSH
- Tumor Necrosis Factor-alpha * antagonists & inhibitors MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Observational Study MeSH
- Names of Substances
- Infliximab MeSH
- Tumor Necrosis Factor-alpha * MeSH
Department of Dermatology and Venerology University Hospital Motol Prague Czech Republic
Department of Pharmacology 2nd Faculty of Medicine Charles University Prague Czech Republic
See more in PubMed
Jourabchi N, Fischer AH, Cimino‐Mathews A, Waters KM, Okoye GA. Squamous cell carcinoma complicating a chronic lesion of hidradenitis suppurativa: a case report and review of the literature. Int Wound J. 2017;14:435–438.
Lavogiez C, Delaporte E, Darras‐Vercambre S, Martin De Lassale E, Castillo C, Mirabel X, et al. Clinicopathological study of 13 cases of squamous cell carcinoma complicating hidradenitis suppurativa. Dermatology. 2010;220:147–153.
Cooper SD, Cowdrey MCE, Linos KD, Lefferts JA, Basic KK. Squamous cell carcinoma in hidradenitis suppurativa lesions following tumor necrosis factor α inhibitors. Cutis. 2021;107:E5–E7.
Kreher MA, Konda S, Noland MMB, Longo MI, Valdes‐Rodriguez R. Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: methotrexate, alkylating agents, biologics, and small molecule inhibitors. J Am Acad Dermatol. 2023;88:534–542.
Li Pomi F, Macca L, Motolese A, Ingrasciotta Y, Berretta M, Guarneri C. Neoplastic implications in patients suffering from hidradenitis suppurativa under systemic treatments. Biomedicine. 2021;9:1594.
Marzano AV, Genovese G, Casazza G, Moltrasio C, Dapavo P, Micali G, et al. Evidence for a ‘window of opportunity’ in hidradenitis suppurativa treated with adalimumab: a retrospective, real‐life multicentre cohort study*. Br J Dermatol. 2021;184:133–140.
Ruggiero A, Lauro W, Miano C, Villani A, Fabbrocini G, Marasca C. Advanced squamous cell carcinoma developed on chronic hidradenitis suppurativa, successfully treated with cemiplimab: a case report. Case Rep Dermatol. 2023;15:35–39.
